Search results
Showing 1 to 15 of 36 results for prostatectomy
NICE is unable to make a recommendation about the use in the NHS of enzalutamide (Xtandi) for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy. This is because Astellas Pharma did not provide an evidence submission.
Show all sections
Sections for TA994
This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.
Evidence-based recommendations on laparoscopic radical prostatectomy. This involves removing the prostate gland and some surrounding tissue using specialised instruments through small cuts in the abdomen (keyhole surgery).
View recommendations for IPG193Show all sections
Sections for IPG193
Evidence-based recommendations on holmium laser prostatectomy. This involves using heat from a laser to break down the extra tissue in the prostate.
Laparoscopic prostatectomy for benign prostatic obstruction (IPG275)
Evidence-based recommendations on laparoscopic prostatectomy for benign prostatic obstruction. This involves removing the prostate through small cuts in the abdomen, using a fine telescope to see inside the body (keyhole surgery).
View recommendations for IPG275Show all sections
Sections for IPG275
Intraoperative red blood cell salvage during radical prostatectomy or radical cystectomy (IPG258)
Evidence-based recommendations on intraoperative red blood cell salvage during radical prostatectomy or radical cystectomy. This involves collecting the solid components of the blood lost during an operation and transfusing it back to the same patient.
View recommendations for IPG258Show all sections
Sections for IPG258
This quality standard covers managing prostate cancer in people referred to secondary care or having follow-up for prostate cancer in primary care. It describes high-quality care in priority areas for improvement.
View quality statements for QS91Show all sections
Sections for QS91
- Quality statements
- Quality statement 1: Discussion with a named nurse specialist
- Quality statement 2: Treatment options
- Quality statement 3: Combination therapy
- Quality statement 4: Managing adverse effects of treatment
- Quality statement 5: Hormone-relapsed metastatic prostate cancer
- Update information
- About this quality standard
Padeliporfin for untreated localised prostate cancer (TA546)
Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults.
Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making
This guideline covers managing lower urinary tract symptoms (LUTS) in men over 18. It aims to improve the quality of life for men with LUTS by recommending which assessments they should receive, and when conservative management, drug treatment and surgery can help.
Low dose rate brachytherapy for localised prostate cancer (IPG132)
Evidence-based recommendations on low dose rate brachytherapy for localised prostate cancer. This involves placing small radioactive seeds into the prostate that give off low doses of radiation to destroy cancer cells.
View recommendations for IPG132Show all sections
Sections for IPG132
Find out about the progress made by the health and care system in implementing NICE guidance on prostate cancer
PLASMA system with button electrode for electrovaporisation of the prostate (MIB274)
NICE has developed a medtech innovation briefing (MIB) on PLASMA system with button electrode for electrovaporisation of the prostate .
Awaiting development [GID-TA11490] Expected publication date: TBC
Axumin for functional imaging of prostate cancer recurrence (MIB172)
NICE has developed a medtech innovation briefing (MIB) on Axumin for functional imaging of prostate cancer recurrence .